Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.52 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24196118 | 0.89 | MAP2K1 (0.52) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL24195910 | 0.88 | MAP2K1 (0.65) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24195795 | 0.88 | MAP2K1 (0.65) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24195671 | 0.87 | MAP2K1 (0.69) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL24195669 | 0.87 | MAP2K1 (0.59) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24195774 | 0.85 | MAP2K1 (0.52) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24195905 | 0.85 | MAP2K1 (0.50) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24196125 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24196123 | 0.84 | MAP2K1 (0.54) | MAP2K1MAP2K2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24196106 | 0.82 | MAP2K1 (0.48) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MEN1 4223/4885KMT2A 620/4885 |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CUTA, BRAF | MAP2K1 469/4885MEN1 2119/4885KMT2A 915/4885 |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | TYR, CUTA, BRAF | MAP2K1 469/4885MEN1 2119/4885KMT2A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.